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Abstract
Background: Explanations for the male-female disability-survival paradox - that woman live longer than men but with more
disability - include sex differences in diseases and their impact on disability and death. Less is known about the paradox in
the very old. We examine sex differences in the presence and impact of disabling and fatal diseases accounting for the male-
female disability-survival paradox in very late life.
Methods: We use data from the Newcastle 85+ Study, a cohort of people born in 1921 and all recruited at age 85 in 2006.
Participants underwent a health assessment (HA) at baseline, 18 months, 36 months, 60 months, and a review of their GP
records (GPRR) at baseline and 36 months. We used multi-state modelling to assess the impact of specific diseases on
disability and death. Disability (measured via ADLs/IADLs) was categorised as no disability (difficulty with 0 activities), or
disabled (difficulty with one or more activities). Diseases were ascertained from review of general practice records and
cognitive impairment which was defined as an sMMSE of 21 or less (from health assessment).
Results: In participants who had complete HA and GPRR, women had more arthritis (RR = 1.2, 95% CI: 1.1–1.3) and
hypertension (RR = 1.2, 95%CI 1.0–1.3), more disability, and were more likely disabled at all follow-ups. From multistate
models, women with cerebrovascular disease (HR: 2.6, 95% CI: 2.1–3.4) or respiratory disease (HR: 2.0, 95% CI: 1.4–3.0) were
more likely to become disabled than those without but this did not hold for men (sex difference p,0.01). Men were more
likely to die from respiratory disease (HR: 2.2, 95% CI: 1.8–2.8) but this did not hold for women (p = 0.002).
Conclusion: The disability-survival paradox was still evident at age 85 and appears due to sex differences in the types of
diseases and their impact on the disability pathway.
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Introduction
Women live longer than men on average, but their longer life
expectancy is accompanied by more years with disability, both in
absolute terms and as a proportion of remaining life [1].
Understanding the basis of this ‘‘disability-survival paradox’’
[2,3] is important for addressing the different health challenges
faced by very old men and women, the fastest growing age group
in many countries [4], and could inform more effective clinical
practice. The paradox may derive from intrinsic differences
(biological, social or behavioural) between men and women
[3,5,6]. Women are reported to have a greater number of acute
and non-fatal chronic diseases, whereas men have fewer diseases in
total but more of these are life-threatening [5,7,8]. A potential
basis for a biological difference between men and women is the
actions of sex hormones. Female sex hormones bring benefits for
women by modulating lipid levels, and hence cardiovascular risk,
and by affecting the immune response [5]. A recent report
describes longer lifespans for Korean eunuchs than intact men,
which is consistent with the idea that male sex hormones, notably
testosterone, may be a risk factor for earlier mortality [9],
notwithstanding the limitations of such historical studies. Behav-
ioural differences between women and men include their
perception of symptoms and readiness to consult with healthcare
professionals. Sex differences in physician diagnostic patterns and
self-reporting of disease may also contribute [10]. It is also possible
that the progression of disease to disability may be more marked
for women than men, especially if women are under-treated for
some conditions [11]. Men’s higher mortality may also result from
a greater severity of disease, which is inadequately captured in
analyses based on the simple presence/absence of a condition. The
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contribution of such distortion has previously been reported to be
small but it cannot altogether be discounted [2].
The Newcastle 85+ Study is a population-based longitudinal
study of health and ageing in the very old. The comprehensive,
multidimensional health assessment performed in this study,
combined with the high level of success in recruiting from this
age group [12], has provided a rich resource from which we can
determine whether there are sex differences in the impact of
specific diseases on disability and survival beyond age 85. More
specifically we have examined the disability-survival paradox with
a single hypothesis in mind: that the gender disparity in mortality
and disability is driven by sex differences in the type of disease and
their impact on disability.
Methods
Recruitment and Study Protocol
The sampling frame for the Newcastle 85+ Study comprised all
surviving adults born in 1921, who turned 85 in 2006 when the
study commenced, and who were permanently registered with a
participating general practice in Newcastle or North Tyneside
NHS Primary Care Trusts in North-East England. Full details of
study design and participant recruitment have been reported [12–
14]. At baseline, participants underwent a detailed multidimen-
sional health assessment conducted by a trained research nurse in
their usual place of residence (own home or institution). Data on
diagnosed diseases (with date of first diagnosis) and prescribed
medication were obtained from participants’ general practice (GP)
medical records. Following baseline assessment, participants were
re-assessed at 18, 36 and 60 months.
Disability Measures
At baseline and follow-up assessments, participants were asked
about their ability to perform 15 activities comprising Instrumental
and Basic Activities of Daily Living (IADLs, BADLs) and mobility
items (Figure 1) [15]; these were taken predominantly from the
Groningen Activity Restriction Scale [16]. As loss of ability for
individual items formed a single hierarchy, similar for men and
women [17], we calculated a disability score scoring 0 for each
item reported to be performed without difficulty and 1 for each
item performed with difficulty (maximum score 15). Participants
were classified as having disability (difficulty with one or more
items) or no disability (difficulty with no items). The association
between self-reported performance in mobility items and an
objectively measured timed-up-and-go (TUG) [18] test was high,
and similar in both men and women [15].
Disease Status
Disease status at baseline was ascertained predominantly from
GP medical records; data extraction was conducted by trained
research nurses following a standard protocol. Inter-rater reliabil-
ity assessment demonstrated at least moderate agreement between
the nurses for all diseases [13]. In the UK, patients are registered
with a single general practice which acts as a gatekeeper to
secondary care and receives details of all hospital admissions and
outpatient attendances. The review of general practice records
included hospital correspondence to ensure that all pre-existing
diagnoses were extracted irrespective of where the diagnosis was
made (from both paper and electronic formats). The only
exception to ascertainment from GP records was for cognitive
impairment, which we defined by a Standardised Mini-Mental
State Examination (SMMSE) score of 21 or below [19]; SMMSE
was conducted as part of the participant health assessment.
For the purpose of this analysis, we focused on the eight most
prevalent diseases in our cohort; in some cases we grouped
multiple conditions into a category (e.g. all arthritic diseases) whilst
other diseases were retained as single entities (e.g. hypertension)
(Figure 2). For each participant we calculated a disease count
(maximum score 8). A further review of GP records was conducted
at 36 months and the SMMSE was re-administered at wave three
and four. Individual diseases and conditions and the disease count
were therefore updated and included in the models as time-
varying covariates.
Mortality
Participants’ medical records were flagged with the National
and Social Care Information Service to provide date and cause of
death. Survival time was calculated from date of baseline health
assessment to date of death or censored at 1st September 2012.
Statistical Methods
Sex differences in the prevalence of each disease were analysed
by Generalised Linear Models and presented as relative risk (RR)
with 95% confidence intervals. We assessed gender differences in
IMD and education at baseline by ordinal logistic regression and
presented them as odds ratios (OR) with 95% confidence intervals.
Sex differences in the level of disability at baseline were analysed
by Tobit regression [20] to account for the ‘floor effects’ in the
disability score and adjusted for: years of full-time education (0–9
years/10–11 years/12+ years); Index of Multiple Deprivation
(IMD), an area level measure of socio-economic disadvantage
(categorised as ,20th centile, 20–80th centile, .80th centile) [21];
and disease count. A similar approach was used to compare sex
differences in baseline disability associated with each specific
disease with adjustment for residual disease count (disease count
excluding the disease of interest), IMD and education. We present
the difference in disability scores with 95% confidence interval.
To assess the contribution of specific diseases to transitions to
and from disability and to death over five years, we fitted a
multistate model in continuous time with three states: no disability,
Figure 1. Intrumental and Basic Activites of Daily Living (IADLs,
BADLs) and mobility items included in the disability score with
possible repsonses.
doi:10.1371/journal.pone.0088016.g001
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disability, and death (absorbing state). We used this model to
estimate the instantaneous rate of transition between the states
(presented as hazard rates with 95% confidence intervals and
mean time in the state) making the assumption that transition from
no disability to death was via disability. Models were fitted with
each disease individually and then adjusted for the residual disease
count. Models were further adjusted for IMD and education.
Since participants were all born in 1921 (and all aged 85 at
baseline) we did not adjust for age in any models. Analyses were
carried out in R version 2.9.1 using the msm package [22].
Ethical Issues
Ethical approval was obtained from Newcastle & North
Tyneside Local Research Ethics Committee One. Written
informed consent was obtained from participants; where people
lacked capacity to consent, for example because of cognitive
impairment, a formal written opinion was sought from a consultee,
usually a relative or carer.
Results
Selection and Key Characteristics of Study Population
At baseline, data from both participant assessment and GP
records was available for 854 participants; 2 people subsequently
withdrew and requested all data destroyed; 2 did not have
complete data on disability and 7 did not have complete GP
records. The remaining 843 had complete data for disability and
disease status and formed the sample for analysis. The majority
(61.9%, n= 522) were female. Of the key characteristics at
baseline, only level of deprivation showed a significant sex
difference with women having higher levels of disadvantage than
men (OR F:M=1.3, 95% CI: 1.0–1.7) (Table 1).
Disease and Disability Prevalence at Baseline
At baseline, women were more likely to have a diagnosis of
arthritis (RR: 1.2, 95% CI: 1.1–1.3) or hypertension (RR: 1.2,
95% CI: 1.0–1.3) and less likely to have a diagnosis of
cerebrovascular disease (CVD) (RR: 0.8, 95% CI: 0.6–1.0)
(Table 1). There was no evidence of any sex difference in the
total number of diseases (p = 0.68) or in disease duration (time
since first diagnosis) for any disease. Table S1 details the disease
duration by gender.
Sex differences in the baseline disability score, between partic-
ipants with and without specific diseases at baseline, demonstrated a
broadly similar disabling impact for men and women (Table 2). For
both sexes, cognitive impairment (SMMSE#21) conferred the
greatest disability, by approximately 7 points compared to those
cognitively intact, then CVDwith a difference in disability score of 3
points in women and 2 in men. Compared to men, women had a
significantly greater disability score at baseline for all diseases except
cognitive impairment and cancer where no difference was evident
(Table 2). Where disease was not present levels of disability
remained higher for women than men across all disease groups even
after adjustment for potential confounders (deprivation, education
and residual disease count).
Overall, women reported difficulty with almost two more
activities on average than men (difference in mean disability score:
2.0, 95% CI: 1.2–2.7), even after adjusting for education,
deprivation and disease count (Table 3).
Impact of Disease on Transitions to Disability and Death
over 5 years
At each of the 18, 36 and 60 month follow-ups, over 70% of
participants remained in the study (18 month: n = 626; 36 months:
n = 482; 60 months: n = 342), 7–12% withdrew (18 month:
n = 151; 36 months: n = 51; 60 months: n = 59) whilst around
15% died (18 month: n= 66; 36 months: n = 92; 60 months:
n = 81) (Table 3).
Higher levels of disability found in women at baseline were also
manifest at subsequent follow-up waves (Table 3). This pattern was
unlikely to result from men being less likely to report difficulty in
performance than women, as the relationship between reported
Figure 2. Conditions examined with data sources and ascertainement criteria.
doi:10.1371/journal.pone.0088016.g002
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performance on mobility items and the objectively measured TUG
test were similar in men and women, at baseline and subsequent
waves. Compared to men, women had higher levels of disability in
the interview prior to dropout, whether dropout was due to death
or withdrawal (Table 3).
We used multistate models to explore sex differences in the
progression to disability and death for each disease after
adjustment for residual disease count, education and deprivation
(Table 4). Diabetes conferred the highest risk of incident disability
in men (HR: 3.0, 95% CI: 2.4–3.8) and women (HR: 1.7, 95% CI:
1.3–2.2) (Table 4). Despite the prevalence of arthritis being highest
in women, its impact on incident disability was greater for men
(HR: 1.7, 95% CI: 1.2–2.5) than women (HR: 1.2, 95% CI: 1.0–
1.5) but arthritis conferred a significantly increased risk of
becoming disabled in both sexes. Both men (HR: 1.6, 95% CI:
1.3–1.9) and women (HR: 2.4, 95% CI: 1.9–3.0) with cardiac
disease had significantly greater risk of incident disability but the
risk was higher for women (p= 0.003). A greater risk of incident
Table 1. Study population key characteristics.
Male (n =321) Female (n =522) All (n =843) P-Value1 Sex Difference (95% CI)
Education (years)
0–9 61.99 (199) 65.71 (343) 64.29 (542) 0.288 0.86 (0.65–1.14)*
10–11 24.92 (80) 21.65 (113) 22.89 (193)
12+ 13.08 (42) 12.64 (66) 12.81 (108)
Area deprivation (measured by IMD)
Low (,25 centile) 29.91 (96) 21.65 (113) 24.79 (209) 0.031 1.33 (1.02–1.74)*
Middle (25–75 centile) 47.04 (151) 52.87 (276) 50.65 (427)
High (.75 centile) 23.05 (74) 25.48 (133) 24.56 (207)
Disease at baseline
Arthritis 60.44 (194) 71.84 (375) 67.50 (569) 0.001 1.19 (1.07–1.32){
Hypertension 52.34 (168) 59.96 (313) 57.06 (481) 0.034 1.15 (1.01–1.30){
Cardiac disease 42.06 (135) 35.63 (186) 38.08 (321) 0.060 0.85 (0.71–1.01){
Cerebrovascular disease 24.61 (79) 18.97 (99) 21.12 (178) 0.050 0.77 (0.59–1.00){
Respiratory disease 22.43 (72) 22.61 (118) 22.54 (190) 0.953 1.01 (0.78–1.30){
Diabetes mellitus 14.33 (46) 12.64 (66) 13.29 (112) 0.483 0.88 (0.62–1.25){
Cognitive impairment 10.28 (33) 14.56 (76) 12.93 (109) 0.076 1.42 (0.96–2.08){
Cancer 8.10 (26) 5.36 (28) 6.41 (54) 0.104 0.65 (0.39–1.09){
Disease count median (mean(sd)) 2.4 (1.3) 2.4 (1.3) 2.4 (1.3) 0.680 0.06 (20.11–0.24)`
*Ordinal logistic regression – Odds ratio - men: women.
{Generalised linear model - Relative Risk - men: women.
`T-test – difference in disease count - men: women.
1P-value for gender difference.
doi:10.1371/journal.pone.0088016.t001
Table 2. Disability by disease status at baseline.
Disability Score - Median (IQR)
Men Women
Sex difference in disability
score{
With
disease
Without
disease
Disability score
difference (95% CI)*
With
disease
Without
disease
Disability score
difference (95% CI)*
With
disease
Without
disease
Arthritis 2 (1–5) 1 (0–4) 1.55 (0.27,2.83) 3(1–7) 2(0–5) 1.68 (0.68,2.67) 1.82 (0.94,2.70) 1.78 (0.32,3.23)
Hypertension 1 (0–4) 2 (0–6) 20.92 (22.16,0.32) 3(1–7) 3(1–7) 0.01 (20.90,0.92) 2.37 (1.39,3.35) 1.51 (0.34,2.69)
Cardiac Disease 2 (0–5) 1 (0–5) 20.17 (21.43,1.09) 4(2–8) 3(1–6) 1.26 (0.34,2.18) 2.80 (1.69,3.90) 1.46 (0.45,2.48)
CVD 2 (1–6) 1 (0–4) 2.15 (0.75,3.56) 6(3–11) 3(1–6) 3.10 (2.01,4.20) 2.99 (1.28,4.69) 1.86 (1.05,2.67)
Respiratory disease 2 (0–5) 1 (0–4) 0.69 (20.79,2.17) 4(2–8) 3(1–6) 0.94 (20.11,2.00) 2.12 (0.68,3.56) 1.92 (1.05,2.80)
Diabetes 2.5 (0–6) 1 (0–4) 0.64 (21.12,2.41) 4(3–7) 3(1–7) 1.18 (20.14,2.51) 2.37 (0.53,4.21) 1.91 (1.09,2.73)
Cognitive Impairment 11 (6–13) 1 (0–3) 7.85 (6.14,9.56) 9(5.5–13.5) 3(1–5) 6.28 (5.15,7.40) 0.37 (22.00,2.74) 1.79 (1.11,2.46)
Cancer 2 (1–3) 1 (0–5) 0.72 (21.46,2.90) 2.5(1–7) 3(1–7) 20.23 (22.22,1.76) 1.19 (21.39,3.77) 2.12 (1.33,2.90)
*Tobit regression: difference in disability score for those with and without disease.
{Tobit regression: sex difference in disability score for those with and without disease: women compared to men.
doi:10.1371/journal.pone.0088016.t002
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disability was also evident for cognitive impairment (men HR: 1.3,
95% CI: 1.1–1.6; women HR: 1.7, 95% CI: 1.0–2.9). On the other
hand CVD (HR: 2.6, 95% CI: 2.1–3.4) and respiratory disease
(HR: 2.0, 95% CI: 1.4–3.0) increased the risk of incident disability
for women only.
Significant sex differences in the risk of death for those without
disability were observed only for cancer (men: HR: 4.1, 95% CI
2.4–7.1; women: HR: 1.1, 95% CI: 0.7–1.9) and respiratory
disease (men: HR: 2.2, 95% CI 1.7–2.8; women: HR: 1.0, 95%
CI: 0.5–2.0) with male participants being at increased risk
compared to their female counterparts (Table 4). Men with
cardiac disease (HR: 1.4, 95% CI: 1.2–1.8) or CVD (HR: 1.3,
95% CI: 1.1–1.6) were at increased risk of death from a non-
disabled state but this did not differ significantly from their female
equivalents. The risk of death from a non-disabled state was
significantly increased for both men and women with cognitive
impairment (men: HR: 1.7, 95% CI: 1.4–2.0; women HR: 1.4,
95% CI: 1.0–1.9).
Recovery from disability was rare and lowest for participants
with cognitive impairment though similarly for men (HR: 0.2,
95% CI: 0.1–0.3) and women (HR: 0.2, 95% CI: 0.03–0.9) and in
both cases significantly less likely compared to participants without
cognitive impairment (Table 4).
Hazard ratios for the risk of death once disabled were of similar
magnitude for those with cognitive impairment (men HR: 2.5, 95%
CI: 1.8–3.5; women HR 2.6, 95% CI: 1.8–3.8) and cardiac disease
(menHR: 1.5, 95%CI: 1.2–1.8; womenHR: 1.4, 95%CI: 1.1–1.8).
CVD increased the risk of death once disabled for women only (HR:
1.4, 95% CI: 1.0–1.8) as did respiratory disease (HR: 1.4, 95% CI:
1.1–1.9) and cancer (HR: 1.5, 95% CI: 1.1–2.1).
The varied way in which different diseases impact on transitions
to and from disability and to death for men and women is
illustrated in Figure 3 for two diseases: cognitive impairment and
respiratory disease. Cognitive impairment confers a very high risk
of disability with little chance of recovery from disability and a
high risk of death, but little difference exists between men and
women. Respiratory disease on the other hand is significantly
disabling only in women and has a higher risk of death for men
initially disability free and women initially disabled.
Mean Time with and without Disability
Overall, and regardless of disease status, more years are spent
after age 85 with disability than without for both men and women,
with women spending 2.2 years more on average with disability
and 0.5 years less without disability than men (Table 5).
For hypertension and arthritis, men and women spent longer
with disability for both sexes than those without the disease,
reflecting the low fatality and disabling effects of these conditions.
This was additionally true for women with diabetes. For any of the
diseases examined, women with the disease spent fewer years
without disability compared to women without the disease. This
was also broadly similar for men although men with hypertension
spent more years (0.35 years) disability-free than men without
hypertension and men with cognitive impairment spent 1.32 years
longer disability-free than men without cognitive impairment.
Discussion
The goal of this paper was to determine potential reasons for the
male-female disability survival paradox in the very old, in
particular the role of specific diseases on disability and mortality.
We approached the investigation with a single question in mind:
was the mortality and disability difference between men and
women primarily driven by sex variation in the type and impact of
diseases [23].
We found that at age 85 women already had a higher
prevalence of disability than men and were more likely to have
arthritis and hypertension. Despite women having marginally less
CVD and cardiac disease than men at age 85, these conditions
resulted in higher disability scores in women at baseline and
prospectively were more likely to be disabling in women.
Respiratory disease was also significantly more disabling in women
than men although prevalence at age 85 was similar for men and
women. Thus from age 85 women spent longer with disability
Table 3. Disability by gender and participation status at baseline and follow-up waves.
Disability Score at
interview
Disability Score at previous
interview
Median (IQR) Median (IQR)
Men Women Sex difference* Men Women Sex difference*
Baseline (n=843) 0 (1–5) 3 (1–7) 1.97 (1.21,2.72) – – –
18 months (Wave 2)
Participant (n = 626) 2 (1–6) 4.5 (2–9) 1.90 (1.11–2.70) 1 (0–4) 3 (1–5.5) 1.79 (1.01–2.58)
Died before W2 (n = 66) – – – 6 (1–12) 9 (4–14) 3.53 (0.29–7.35)
Withdrawn before W2 (n = 151) – – – 2 (1–6) 5 (2–9) 2.54 (0.85–4.24)
36 months (Wave 3)
Participant (n = 482) 4 (1–8) 5 (3–9) 1.33 (0.41–2.26) 2 (1–6) 4 (2–7) 1.76 (0.91–2.61)
Died before W3 (n = 52) – – – 5 (2–8) 11 (3–14) 4.23 (1.06–7.40)
Withdrawn before W3 (n = 92) – – – 3 (1–8) 7 (4–12) 2.29 (0.20–4.39)
60 months (Wave 4)
Participant (n = 342) 4 (1–7) 5 (3–9) 1.74 (0.60–2.87) 3 (1–7) 4 (3–7) 1.04 (0.55–2.02)
Died before W4 (n = 81) – – – 5 (1–10) 11 (5–13) 2.98 (0.51–5.44)
Withdrawn before (n = 59) – – – 5 (1.5–10.5) 7 (3–11) 2.20 (20.95–5.35)
*Tobit regression sex difference compared women to men.
doi:10.1371/journal.pone.0088016.t003
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than men overall (on average 2.2 years) and by disease. No sex
differences were found in disease-specific recovery from disability
and only for cancer was there a sex difference in disease-specific
risk of death. These findings were not a consequence of differences
in education, current socio-economic status (as measured by IMD)
or the presence of comorbidity. Neither were they due to men with
more disability dying or withdrawing between assessments as
comparison of disability scores in the interview prior to death or
withdrawal again demonstrated excess disability in women over
men. Thus we suggest that the disability-survival paradox in the
very old is at least partly due to sex differences in the type and
disabling impacts of diseases.
Very old men have a marginally greater prevalence of diseases
which are more likely to kill (cardiac disease, CVD and cancer),
and women a higher prevalence of the chronic diseases (arthritis
and hypertension). Nevertheless, this difference did not always
translate to increased disability incidence or death. Arthritis was
more disabling for men and cardiac disease for women, whilst
cancer and cognitive impairment were the most fatal diseases for
women (after becoming disabled). Earlier studies, mainly in
younger age groups, have found that women are significantly
more likely than men of the same age to have disabling rather than
fatal diseases [3,5,6]. We can confirm that very old women (85+)
do have a significantly greater prevalence of chronic diseases
Table 4. Hazard rates (HR) and 95% confidence intervals (95% CI) for transitions between disability states and death adjusted for
comorbidity, deprivation, and education.
Men Women Sex Difference p-value
Incident Disability Referent* 1.26 (1.12–1.41) 0.041
Arthritis 1.72 (1.19–2.48) 1.23(1.02–1.49) 0.942
Hypertension 0.87 (0.48–1.58) 1.09(0.56–2.12) 0.315
Cardiac Disease 1.60 (1.32–1.93) 2.39(1.92–2.97) 0.003
Cerebrovascular Disease 1.11 (0.76–1.63) 2.63(2.06–3.35) 0.000
Respiratory disease 0.98 (0.74–1.29) 2.02(1.35–3.01) 0.002
Diabetes 3.03 (2.43–3.79) 1.67(1.26–2.22) 0.001
Cognitive Impairment 1.31 (1.06–1.62) 1.71 (1.02–2.86) 0.174
Cancer 0.84 (0.29–2.42) 1.85(0.71–4.80) 0.139
Death from no disability Referent* 0.89(0.73–1.08) 0.216
Arthritis 0.70 (0.33–1.50) 0.99(0.47–2.13) 0.260
Hypertension 0.62 (0.28–1.34) 1.01(0.44–2.31) 0.200
Cardiac Disease 1.42 (1.17–1.73) 1.48 (0.97–2.26) 0.569
Cerebrovascular Disease 1.31 (1.09–1.57) 1.00(0.59–1.70) 0.173
Respiratory disease 2.16 (1.67–2.79) 1.00(0.49–2.04) 0.046
Diabetes 1.20 (0.88–1.62) 1.01(0.24–4.17) 0.592
Cognitive Impairment 1.68 (1.41–2.01) 1.38(1.01–1.89) 0.857
Cancer 4.10 (2.35–7.13) 1.10(0.65–1.86) 0.001
Disability recovery Referent* 0.96 (0.80–1.15) 0.328
Arthritis 0.73 (0.42–1.28) 0.96(0.72–1.27) 0.196
Hypertension 1.63 (0.94–2.81) 0.79(0.30–2.08) 0.899
Cardiac Disease 0.94 (0.57–1.56) 0.96(0.49–1.88) 0.481
Cerebrovascular Disease 1.63 (0.50–5.38) 0.41(0.03–5.03) 0.837
Respiratory disease 1.07 (0.58–1.97) 0.82(0.26–2.66) 0.651
Diabetes 0.85 (0.28–2.57) 0.89(0.54–1.47) 0.470
Cognitive Impairment 0.17 (0.09–0.31) 0.17(0.03–0.88) 0.500
Cancer 0.94 (0.67–1.33) 0.90(0.53–1.54) 0.547
Death from disabled Referent* 0.84 (0.72–0.98) 0.042
Arthritis 0.84 (0.61–1.17) 0.92(0.51–1.66) 0.403
Hypertension 0.81 (0.59–1.10) 1.08(0.76–1.52) 0.111
Cardiac Disease 1.46 (1.21–1.77) 1.40(1.11–1.78) 0.601
Cerebrovascular Disease 1.09 (0.62–1.92) 1.36(1.03–1.80) 0.244
Respiratory disease 1.39 (0.82–2.35) 1.42(1.05–1.92) 0.474
Diabetes 1.27 (0.87–1.87) 1.11(0.76–1.63) 0.693
Cognitive Impairment 2.49 (1.76–3.54) 2.62(1.81–3.78) 0.428
Cancer 1.43 (0.92–2.22) 1.51(1.10–2.08) 0.416
*Referent category for assessing gender difference adjusted for full disease count.
doi:10.1371/journal.pone.0088016.t004
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(arthritis, hypertension). Whilst men of the same age had greater
prevalence of fatal diseases (cardiac disease, CVD and cancer)
than women the differences were not statistically significantly
different. Furthermore, the presence of certain fatal diseases
increased the likelihood of incident disability more for women than
men and increased the likelihood of death from a non-disabled
state more for men than women.
Longitudinally, the presence of arthritis, cardiac disease,
diabetes and cognitive impairment was significantly disabling for
both sexes and CVD and respiratory disease for women only. This
is generally consistent with previous findings [24] although in our
study CVD and respiratory disease were significantly disabling in
women only, perhaps caused by slight differences in criteria
considered for a CVD diagnosis that may favour women
compared to other studies. Furthermore we found cardiac disease,
CVD, and respiratory disease to be more disabling for women
compared with men whilst cognitive impairment was similarly
disabling in both sexes. Diabetes was also disabling for both sexes,
however the impact was noticeably worse for men (HR: 3.0, 95%
CI: 2.4–3.8) compared to women (HR: 1.7, 95% CI: 1.3–2.2)
(p = 0.001).
Implications for Clinical Practice
Few recoveries from disability were observed regardless of the
presence or absence of specific diseases, and were particularly low
in the presence of cognitive impairment. Indeed cognitive
impairment was detrimental for disability incidence, recovery
and mortality for both sexes as previously found [24–26]. Gill et al
analysed trajectories of disability on a monthly basis [27] and
showed that among people in advanced stages of dementia, 67.9%
had persistent severe disability. Our results similarly showed that
those who became cognitively impaired moved swiftly into
disability and then death (figure 3). This adds to the already
strong argument for better preventative care in those at higher risk
of developing cognitive impairment, especially as projection
modelling from large cohort studies has predicted the link between
ageing populations, dementia and disability. Despite concerns
about screening for mild cognitive impairment and dementia [28]
the very old should perhaps be considered a ‘high risk’ population
worthy of targeted case finding, in view of our findings and the fast
progression from cognitive impairment to disability [29]. Further-
more, cognitive impairment was shown to be the most disabling
disease, confirming its importance as a primary determinant of
disability [30]. Using the same measure of cognitive impairment, a
UK study reported that its elimination would save around 3.5 total
life years and 4.3 years free of disability at age 65, and therefore
with a greater impact on disability. In terms of slowing the
deterioration in global functioning of people with dementia, anti-
cholinesterase drugs have been shown to be cost-effective in both
the early and moderate stages of Alzheimer’s disease [31], with
recent evidence showing benefit also in advanced stages [32].
Evidence is growing around the effectiveness of some non-drug
interventions, such as cognitive stimulation in routine dementia
care, although there remains uncertainty about the most cost-
Figure 3. Transition probabilties for two diseases by gender.
doi:10.1371/journal.pone.0088016.g003
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effective way of delivering such interventions in practice. There is
also an increasingly strong argument for better preventative care
in those at higher risk of developing dementia. Based on our
findings this may be particularly the case for women. More timely
diagnoses would lead to earlier intervention which may delay the
onset of significant disability from the moderate and advanced
stages of cognitive impairment.
Greater fatality in men with respiratory disease (with no
disability) may explain the greater disabling impact observed in
women, by means of accelerated transit through the disablement
process to death for men, a process for which we found no
evidence in women. However the greater disabling impact of
cardiac disease and CVD in women cannot be explained this way.
Global estimates of the prevalence of angina have been shown to
be significantly greater for women but men diagnosed with the
same disease have an excess MI [33]. Whilst little is known about
the etiological causes it could go some way to explain our results
since, if men diagnosed with angina are at greater risk of MI [34]
compared with their female counterparts, they may be more likely
to die before we could detect disability. Our results indicate that
cardiac disease is disabling for both men and women but such men
have increased mortality whilst this is not true for women.
However, once disabled, men and women with cardiac disease are
more likely to die than their counterparts without the disease. This
suggests that care packages for those with cardiac disease should
be tailored towards reducing mortality in men and reducing
disability in both sexes.
Strengths and Limitations
Our study has strengths and limitations mainly in regard
to measurement of disease and disability. That sex differences in
self-reported disease were avoided in our study, as disease was
ascertained from general practice records, can be viewed as both a
strength and a limitation. Whilst in general women are more likely
to consult health professionals than men, general practitioner
consultation rates among the very old are high overall, and in our
study did not differ between men and women. However we had
previously found that women had lower rates of outpatient
attendance than men [13]. Our diagnosis of disease was an ‘ever’
diagnosis (with the exception of cancer which was within the
previous five years only) and we did not have information on
disease severity, though analysis of disease duration showed no
significant sex difference. Given disease was ascertained from
general practice records, there may have been sex differences in
undiagnosed disease. Through further measurements in the health
assessment we have explored rates of undiagnosed disease for
diabetes and hypertension and found rates of undiagnosed
diabetes were low with no sex difference and, though the
prevalence of undiagnosed hypertension was high (based on a
single-occasion blood pressure measurement) again no sex
difference was detected [13]. A further strength is that we
investigated two levels of disability, milder and more severe, but
this did not alter the conclusions. Finally, self-report of mobility
items included in the disability score were highly correlated with
objective measures (timed up-and-go) similarly in men and
women.
Conclusion
Once health deteriorates, mortality rates increase more for men
than women [35] and this is revealed in our results where the
impacts of certain diseases are disabling for women but
detrimental to survival for men. Men who encounter diseases
Table 5. Mean sojourn times in state (years) by disease group.
Without disability With Disability
Without disease With disease Without disease With disease
Women
1.31 6.44
Arthritis 1.47 1.20 6.12 6.51
Hypertension 1.37 1.26 5.97 6.70
Cardiac Disease 1.53 0.64 6.95 5.29
CVD 1.38 0.53 6.61 5.67
Respiratory disease 1.46 0.72 6.86 5.26
Diabetes 3.46 2.07 4.36 5.20
Cognitive Impairment 3.58 2.23 4.64 3.04
Cancer 1.36 0.73 6.58 4.67
Men
1.82 4.20
Arthritis 2.52 1.60 4.09 5.11
Hypertension 1.87 2.22 4.34 5.00
Cardiac Disease 2.46 1.57 5.44 3.88
CVD 2.12 1.92 4.85 4.25
Respiratory disease 2.15 1.56 4.74 3.89
Diabetes 2.28 0.81 4.86 3.97
Cognitive Impairment 2.04 3.36 5.21 2.41
Cancer 2.04 1.81 4.79 3.43
doi:10.1371/journal.pone.0088016.t005
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which increase mortality could be accelerated through the
disability pathway [36] (and ultimately death). However the time
intervals of our study are too wide to capture this potential,
accelerated transit. Nevertheless, if, as posited, men traverse the
disablement process faster than women once they encounter
disease, it would further suggest that they do not just ‘age faster’
biologically than women [37]. We suggest that our results point to
two different biological mechanisms driving the male-female
disability-survival paradox: the sex difference is driven by a female
heath disadvantage as well as being accompanied by a female
mortality advantage, consistent with other findings [38–40]. Our
results suggest that the potential acceleration through the
disablement pathway for men may be caused by the gender-
specific effect of disease (and severity) and/or its potential
subsequent sequelae. Alternatively, it could be that men and
women follow different routes through the disability pathway and
thus women will, intrinsically, always show more disability than
men at a population level [41]. Exploration of the biological
mechanisms underlying the sex differences may assist our
understanding and point the way to interventions to prevent or
ameliorate the disabling effects of diseases.
By age 85 women have significantly more disability and
disabling diseases such as arthritis and hypertension. Whilst
hypertension may be asymptomatic, its potential sequelae such as
ischemic heart disease, heart failure and CVA could be the driving
forces behind its disabling effects. Although men have slightly,
though not significantly, more fatal diseases (cardiac disease and
CVD), women with these diseases, as well as with respiratory
disease, are more likely to become disabled. Men without disability
are significantly more likely to die from cancer and respiratory
disease but all other transitions from a disabled or non-disabled
state were similar for men and women. In addition, we found that
overall disability was more of a risk factor for male mortality
(disease count adjusted) compared to women and is supported by
recent findings [42].
We conclude that the disability-survival paradox is still evident
in the very old and appears due to sex differences in the types and
impacts of disease.
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